[{"orgOrder":0,"company":"ABL Bio","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Antibody","year":"2025","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"ABL Bio","amount2":2.73,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":2.73,"dosageForm":"Undisclosed","sponsorNew":"ABL Bio \/ GSK","highestDevelopmentStatusID":"1","companyTruncated":"ABL Bio \/ GSK"},{"orgOrder":0,"company":"Queen Mary University of London","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Cladribine","moa":"DNA polymerase","graph1":"Neurology","graph2":"Undisclosed","graph3":"Queen Mary University of London","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Queen Mary University of London \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Queen Mary University of London \/ Inapplicable"},{"orgOrder":0,"company":"Vizient","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Vizient","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vizient \/ Pfizer Inc","highestDevelopmentStatusID":"1","companyTruncated":"Vizient \/ Pfizer Inc"},{"orgOrder":0,"company":"Undisclosed","sponsor":"Bionxt Solutions","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Cytotoxic Drug","year":"2023","type":"Agreement","leadProduct":"Cladribine","moa":"DNA polymerase","graph1":"Neurology","graph2":"Undisclosed","graph3":"Undisclosed","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Undisclosed \/ Bionxt Solutions","highestDevelopmentStatusID":"1","companyTruncated":"Undisclosed \/ Bionxt Solutions"},{"orgOrder":0,"company":"Undisclosed","sponsor":"Tris Pharma Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"TRN-261","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Undisclosed","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Undisclosed \/ Tris Pharma Inc","highestDevelopmentStatusID":"1","companyTruncated":"Undisclosed \/ Tris Pharma Inc"},{"orgOrder":0,"company":"Akome Biotech","sponsor":"Core One Labs","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Akome Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Akome Biotech \/ Core One Labs","highestDevelopmentStatusID":"1","companyTruncated":"Akome Biotech \/ Core One Labs"},{"orgOrder":0,"company":"Core One Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Psilocybine","moa":"||5-HT2A receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Core One Labs","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Core One Labs \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Core One Labs \/ Inapplicable"},{"orgOrder":0,"company":"InMed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Cannabinoid","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"InMed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"InMed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"InMed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Inflammasome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"NLRP3","graph1":"Neurology","graph2":"Undisclosed","graph3":"Inflammasome Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Inflammasome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Inflammasome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Zylo Therapeutics","sponsor":"Silo Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Agreement","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Zylo Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Injection","sponsorNew":"Zylo Therapeutics \/ Silo Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Zylo Therapeutics \/ Silo Pharma"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"GNE-0723","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Enveric Biosciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveric Biosciences \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Enveric Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Cyclica","sponsor":"Arctoris","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Peptide","year":"2022","type":"Partnership","leadProduct":"Cyclosporine","moa":"Calcineurin","graph1":"Neurology","graph2":"Undisclosed","graph3":"Cyclica","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cyclica \/ Arctoris","highestDevelopmentStatusID":"1","companyTruncated":"Cyclica \/ Arctoris"},{"orgOrder":0,"company":"AIkido Pharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"PPeptide-conjugated Ketamine","moa":"Glutamate allosteic receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"AIkido Pharm","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AIkido Pharm \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"AIkido Pharm \/ Inapplicable"},{"orgOrder":0,"company":"Scribe Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Scribe Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Scribe Therapeutics \/ Biogen","highestDevelopmentStatusID":"1","companyTruncated":"Scribe Therapeutics \/ Biogen"},{"orgOrder":0,"company":"Scribe Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Scribe Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Scribe Therapeutics \/ Biogen","highestDevelopmentStatusID":"1","companyTruncated":"Scribe Therapeutics \/ Biogen"},{"orgOrder":0,"company":"Anew Medical","sponsor":"Redwoods Acquisition Corp.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Merger","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Anew Medical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Anew Medical \/ Redwoods Acquisition Corp.","highestDevelopmentStatusID":"1","companyTruncated":"Anew Medical \/ Redwoods Acquisition Corp."},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"JOS Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Agreement","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Catalent Pharma Solutions \/ JOS Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Catalent Pharma Solutions \/ JOS Pharmaceuticals"},{"orgOrder":0,"company":"Zelira Therapeutics","sponsor":"Forman Investment Trust","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2024","type":"Financing","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Zelira Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oil","sponsorNew":"Zelira Therapeutics \/ Forman Investment Trust","highestDevelopmentStatusID":"1","companyTruncated":"Zelira Therapeutics \/ Forman Investment Trust"},{"orgOrder":0,"company":"Zelira Therapeutics","sponsor":"Forman Investment Trust","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2024","type":"Financing","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Zelira Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oil","sponsorNew":"Zelira Therapeutics \/ Forman Investment Trust","highestDevelopmentStatusID":"1","companyTruncated":"Zelira Therapeutics \/ Forman Investment Trust"},{"orgOrder":0,"company":"Zelira Therapeutics","sponsor":"Forman Investment Trust","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2023","type":"Financing","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Zelira Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oil","sponsorNew":"Zelira Therapeutics \/ Forman Investment Trust","highestDevelopmentStatusID":"1","companyTruncated":"Zelira Therapeutics \/ Forman Investment Trust"},{"orgOrder":0,"company":"SciSparc","sponsor":"Soroka Medical Center","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2023","type":"Agreement","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SciSparc \/ Soroka Medical Center","highestDevelopmentStatusID":"1","companyTruncated":"SciSparc \/ Soroka Medical Center"},{"orgOrder":0,"company":"Elysium Health","sponsor":"University of Oxford","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Elysium Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elysium Health \/ University of Oxford","highestDevelopmentStatusID":"1","companyTruncated":"Elysium Health \/ University of Oxford"},{"orgOrder":0,"company":"Panaxia","sponsor":"Neuraxpharm","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"CB receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Panaxia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Panaxia \/ Neuraxpharm","highestDevelopmentStatusID":"1","companyTruncated":"Panaxia \/ Neuraxpharm"},{"orgOrder":0,"company":"Oxford Biomedica","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Oxford Biomedica","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oxford Biomedica \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Oxford Biomedica \/ Undisclosed"},{"orgOrder":0,"company":"Affinia Therapeutics","sponsor":"Atlas Venture","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Affinia Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Affinia Therapeutics \/ Atlas Venture","highestDevelopmentStatusID":"1","companyTruncated":"Affinia Therapeutics \/ Atlas Venture"},{"orgOrder":0,"company":"Axial Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Axial Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Axial Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Axial Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akums Drugs & Pharmaceuticals Ltd","sponsor":"Biophore India Pharmaceuticals Pvt Ltd","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"INDIA","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Akums Drugs & Pharmaceuticals Ltd","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Akums Drugs & Pharmaceuticals Ltd \/ Biophore India Pharmaceuticals Pvt Ltd","highestDevelopmentStatusID":"1","companyTruncated":"Akums Drugs & Pharmaceuticals Ltd \/ Biophore India Pharmaceuticals Pvt Ltd"},{"orgOrder":0,"company":"University of Pennsylvania","sponsor":"Passage Bio","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"University of Pennsylvania","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"University of Pennsylvania \/ Passage Bio","highestDevelopmentStatusID":"1","companyTruncated":"University of Pennsylvania \/ Passage Bio"},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"PharmAla Biotech","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"MSP-1014","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Mindset Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mindset Pharma \/ PharmAla Biotech","highestDevelopmentStatusID":"1","companyTruncated":"Mindset Pharma \/ PharmAla Biotech"},{"orgOrder":0,"company":"MycoMedica Life Sciences","sponsor":"Obvious Ventures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Financing","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"MycoMedica Life Sciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MycoMedica Life Sciences \/ Obvious Ventures","highestDevelopmentStatusID":"1","companyTruncated":"MycoMedica Life Sciences \/ Obvious Ventures"},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Solarvest BioEnergy","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Cannabinoid","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"FSD Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FSD Pharma \/ Solarvest BioEnergy","highestDevelopmentStatusID":"1","companyTruncated":"FSD Pharma \/ Solarvest BioEnergy"},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Carnegie Mellon University","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Agreement","leadProduct":"Treg-Derived Exosome","moa":"T-cell","graph1":"Neurology","graph2":"Undisclosed","graph3":"Coya Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Coya Therapeutics \/ Carnegie Mellon University","highestDevelopmentStatusID":"1","companyTruncated":"Coya Therapeutics \/ Carnegie Mellon University"},{"orgOrder":0,"company":"UT Southwestern","sponsor":"Taysha Gene Therapies","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Partnership","leadProduct":"TGTX-101","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"UT Southwestern","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UT Southwestern \/ Taysha Gene Therapies","highestDevelopmentStatusID":"1","companyTruncated":"UT Southwestern \/ Taysha Gene Therapies"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Kazia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Paxalisib","moa":"PI3K\/AKT\/mTOR","graph1":"Neurology","graph2":"Undisclosed","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Dana-Farber Cancer Institute \/ Kazia Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Dana-Farber Cancer Institute \/ Kazia Therapeutics"},{"orgOrder":0,"company":"Avextra","sponsor":"German Pain Association","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"GERMANY","productType":"Controlled Substance","year":"2024","type":"Collaboration","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Avextra","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avextra \/ German Pain Association","highestDevelopmentStatusID":"1","companyTruncated":"Avextra \/ German Pain Association"},{"orgOrder":0,"company":"Fathom Pharma","sponsor":"Consegna Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"FP01","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Fathom Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fathom Pharma \/ Consegna Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Fathom Pharma \/ Consegna Pharma"},{"orgOrder":0,"company":"Stevanato Group","sponsor":"Bexson Biomedical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ITALY","productType":"Controlled Substance","year":"2020","type":"Collaboration","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Stevanato Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stevanato Group \/ Bexson Biomedical","highestDevelopmentStatusID":"1","companyTruncated":"Stevanato Group \/ Bexson Biomedical"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dihydrohonokiol-B","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BetterLife Pharma \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"BetterLife Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Cobra Biologics","sponsor":"CombiGene","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"CG01","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Cobra Biologics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cobra Biologics \/ CombiGene","highestDevelopmentStatusID":"1","companyTruncated":"Cobra Biologics \/ CombiGene"},{"orgOrder":0,"company":"Cobra Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"CG01","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Cobra Biologics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cobra Biologics \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Cobra Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Topiramate","moa":"GABA-alpha-1 receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Eton Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Eton Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Topiramate","moa":"GABA-alpha-1 receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Eton Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Eton Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Neuro3 Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"DENMARK","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"H. Lundbeck AS \/ Neuro3 Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"H. Lundbeck AS \/ Neuro3 Therapeutics"},{"orgOrder":0,"company":"Redpin Therapeutics","sponsor":"Kriya Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Redpin Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Redpin Therapeutics \/ Kriya Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Redpin Therapeutics \/ Kriya Therapeutics"},{"orgOrder":0,"company":"Advanced Neural Dynamics","sponsor":"Neuropathix","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Advanced Neural Dynamics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Advanced Neural Dynamics \/ Neuropathix","highestDevelopmentStatusID":"1","companyTruncated":"Advanced Neural Dynamics \/ Neuropathix"},{"orgOrder":0,"company":"Kaleido Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"KB174","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Kaleido Biosciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kaleido Biosciences \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Kaleido Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Locate Bio","sponsor":"Mercia Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Protein","year":"2021","type":"Funding","leadProduct":"rhBMP-2","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Locate Bio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Locate Bio \/ Mercia Asset Management","highestDevelopmentStatusID":"1","companyTruncated":"Locate Bio \/ Mercia Asset Management"},{"orgOrder":0,"company":"PicnicHealth","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"PicnicHealth","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"PicnicHealth \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"1","companyTruncated":"PicnicHealth \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Oscine","sponsor":"Sana Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Oscine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oscine \/ Sana Biotechnology","highestDevelopmentStatusID":"1","companyTruncated":"Oscine \/ Sana Biotechnology"},{"orgOrder":0,"company":"Autobahn Therapeutics","sponsor":"Arch Ventures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series B Financing","leadProduct":"Methyl Amide Prodrug","moa":"TR-beta","graph1":"Neurology","graph2":"Undisclosed","graph3":"Autobahn Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Autobahn Therapeutics \/ Arch Ventures","highestDevelopmentStatusID":"1","companyTruncated":"Autobahn Therapeutics \/ Arch Ventures"},{"orgOrder":0,"company":"Halberd Corporation","sponsor":"Hamden Group","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Naltrexone Hydrochloride","moa":"Kappa\/Mu\/delta-Opioid receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Halberd Corporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Halberd Corporation \/ Hamden Group","highestDevelopmentStatusID":"1","companyTruncated":"Halberd Corporation \/ Hamden Group"},{"orgOrder":0,"company":"Progreso y Salud Foundation","sponsor":"Amarna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SPAIN","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"SVec","moa":"AChE","graph1":"Neurology","graph2":"Undisclosed","graph3":"Progreso y Salud Foundation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Progreso y Salud Foundation \/ Amarna Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Progreso y Salud Foundation \/ Amarna Therapeutics"},{"orgOrder":0,"company":"Medicinova","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ibudilast","moa":"||PDE4","graph1":"Neurology","graph2":"Undisclosed","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medicinova \/ National Institutes of Health","highestDevelopmentStatusID":"1","companyTruncated":"Medicinova \/ National Institutes of Health"},{"orgOrder":0,"company":"Dewpoint Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Dewpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dewpoint Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"1","companyTruncated":"Dewpoint Therapeutics \/ Pfizer Inc"},{"orgOrder":0,"company":"NeuroCycle Therapeutics","sponsor":"Engrail Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Acquisition","leadProduct":"Undisclosed","moa":"GABAA receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"NeuroCycle Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NeuroCycle Therapeutics \/ Engrail Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"NeuroCycle Therapeutics \/ Engrail Therapeutics"},{"orgOrder":0,"company":"Ginkgo Bioworks","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Ginkgo Bioworks","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ginkgo Bioworks \/ Biogen","highestDevelopmentStatusID":"1","companyTruncated":"Ginkgo Bioworks \/ Biogen"},{"orgOrder":0,"company":"Avicanna","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Cannabinoid","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Avicanna","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Sustained Release","sponsorNew":"Avicanna \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Avicanna \/ Inapplicable"},{"orgOrder":0,"company":"Tetra Pharm Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"DENMARK","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Tetra Pharm Technologies","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tetra Pharm Technologies \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Tetra Pharm Technologies \/ Undisclosed"},{"orgOrder":0,"company":"AlzeCure Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"AlzeCure Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AlzeCure Pharma \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"AlzeCure Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Raya Therapeutic","sponsor":"Argenx","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Raya Therapeutic","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Raya Therapeutic \/ Argenx","highestDevelopmentStatusID":"1","companyTruncated":"Raya Therapeutic \/ Argenx"},{"orgOrder":0,"company":"Sunshine Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Sunshine Biopharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sunshine Biopharma \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Sunshine Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Evotec","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"Induced Pluripotent Stem Cell","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evotec \/ Bristol Myers Squibb","highestDevelopmentStatusID":"1","companyTruncated":"Evotec \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"AIkido Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Licensing Agreement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"AIkido Pharm","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AIkido Pharm \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"AIkido Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Codiak BioSciences","sponsor":"Sarepta Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Codiak BioSciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Codiak BioSciences \/ Sarepta Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Codiak BioSciences \/ Sarepta Therapeutics"},{"orgOrder":0,"company":"Medisol","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FRANCE","productType":"Undisclosed","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Medisol","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medisol \/ Lupin Ltd","highestDevelopmentStatusID":"1","companyTruncated":"Medisol \/ Lupin Ltd"},{"orgOrder":0,"company":"Akums Drugs & Pharmaceuticals Ltd","sponsor":"Lyrus Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"INDIA","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Akums Drugs & Pharmaceuticals Ltd","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Akums Drugs & Pharmaceuticals Ltd \/ Lyrus Life Sciences","highestDevelopmentStatusID":"1","companyTruncated":"Akums Drugs & Pharmaceuticals Ltd \/ Lyrus Life Sciences"},{"orgOrder":0,"company":"Pocono Coated Product","sponsor":"Nutriband","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Pocono Coated Product","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pocono Coated Product \/ Nutriband","highestDevelopmentStatusID":"1","companyTruncated":"Pocono Coated Product \/ Nutriband"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Loxicodegol","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Nektar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Nektar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"University of California","sponsor":"AmbioPharm","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Thrixopelma Pruriens Venom Peptide","moa":"NaV1.7 channel","graph1":"Neurology","graph2":"Undisclosed","graph3":"University of California","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California \/ AmbioPharm","highestDevelopmentStatusID":"1","companyTruncated":"University of California \/ AmbioPharm"},{"orgOrder":0,"company":"Travecta Therapeutics","sponsor":"Tks1","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series A Financing","leadProduct":"TVT-004","moa":"CB receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Travecta Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Travecta Therapeutics \/ Tks1","highestDevelopmentStatusID":"1","companyTruncated":"Travecta Therapeutics \/ Tks1"},{"orgOrder":0,"company":"Silo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Licensing Agreement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Silo Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Silo Pharma \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Silo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Syntrix Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Desmetramadol","moa":"Opioid mu receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Syntrix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syntrix Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Syntrix Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Dizlin Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Etilevodopa","moa":"||D3 receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Dizlin Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dizlin Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Dizlin Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lysogene","sponsor":"Weizmann Institute Of Science","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FRANCE","productType":"Undisclosed","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Lysogene","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Lysogene \/ Weizmann Institute Of Science","highestDevelopmentStatusID":"1","companyTruncated":"Lysogene \/ Weizmann Institute Of Science"},{"orgOrder":0,"company":"Oncodesign","sponsor":"Servier","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FRANCE","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"LRRK2","graph1":"Neurology","graph2":"Undisclosed","graph3":"Oncodesign","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Oncodesign \/ Servier","highestDevelopmentStatusID":"1","companyTruncated":"Oncodesign \/ Servier"},{"orgOrder":0,"company":"Autotelic Bio","sponsor":"Oncotelic Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Apomorphine Hydrochloride","moa":"D2\/D3\/D4\/D5 receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Autotelic Bio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Autotelic Bio \/ Oncotelic Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Autotelic Bio \/ Oncotelic Therapeutics"},{"orgOrder":0,"company":"Autotelic Bio","sponsor":"Oncotelic Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Apomorphine Hydrochloride","moa":"D2\/D3\/D4\/D5 receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Autotelic Bio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Autotelic Bio \/ Oncotelic Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Autotelic Bio \/ Oncotelic Therapeutics"},{"orgOrder":0,"company":"Zhittya Genesis Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Zhittya Genesis Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Zhittya Genesis Medicine \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Zhittya Genesis Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Parkinson\u2019s Foundation","sponsor":"Zelira Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"CB receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Parkinson\u2019s Foundation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Parkinson\u2019s Foundation \/ Zelira Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Parkinson\u2019s Foundation \/ Zelira Therapeutics"},{"orgOrder":0,"company":"Kashiv Specialty Pharmaceuticals","sponsor":"Amneal Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"K102","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Kashiv Specialty Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kashiv Specialty Pharmaceuticals \/ Amneal Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Kashiv Specialty Pharmaceuticals \/ Amneal Pharmaceuticals"},{"orgOrder":0,"company":"TissueTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"TTAX02","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"TissueTech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TissueTech \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"TissueTech \/ Inapplicable"},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"APRINOIA Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Tau aggregation","graph1":"Neurology","graph2":"Undisclosed","graph3":"Samsung Biologics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Samsung Biologics \/ APRINOIA Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Samsung Biologics \/ APRINOIA Therapeutics"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Benztropine","moa":"M1 receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Crossject","sponsor":"Eton Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FRANCE","productType":"Steroid","year":"2025","type":"Collaboration","leadProduct":"Hydrocortisone","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Crossject","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Crossject \/ Eton Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Crossject \/ Eton Pharmaceuticals"}]
Find Novel Neurology Drugs in Clinical Development in UNITED STATES
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
